81,800 Shares in TransEnterix, Inc. (NYSEAMERICAN:TRXC) Acquired by Prospera Financial Services Inc

Prospera Financial Services Inc bought a new position in shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) in the 2nd quarter, HoldingsChannel.com reports. The fund bought 81,800 shares of the medical instruments supplier’s stock, valued at approximately $195,000.

A number of other hedge funds have also bought and sold shares of the business. Sheets Smith Wealth Management increased its stake in TransEnterix by 100.0% during the first quarter. Sheets Smith Wealth Management now owns 20,000 shares of the medical instruments supplier’s stock worth $48,000 after acquiring an additional 10,000 shares during the last quarter. Tradewinds Capital Management LLC grew its stake in shares of TransEnterix by 1,222.2% in the second quarter. Tradewinds Capital Management LLC now owns 23,800 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 22,000 shares in the last quarter. Swiss National Bank grew its stake in shares of TransEnterix by 8.9% in the second quarter. Swiss National Bank now owns 343,300 shares of the medical instruments supplier’s stock valued at $467,000 after buying an additional 28,200 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of TransEnterix by 3,781.0% in the first quarter. BNP Paribas Arbitrage SA now owns 35,162 shares of the medical instruments supplier’s stock valued at $84,000 after buying an additional 34,256 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of TransEnterix by 45.9% in the fourth quarter. Bank of America Corp DE now owns 129,949 shares of the medical instruments supplier’s stock valued at $294,000 after buying an additional 40,852 shares in the last quarter.

A number of equities research analysts have recently weighed in on TRXC shares. Zacks Investment Research cut TransEnterix from a “hold” rating to a “sell” rating in a research note on Saturday, July 13th. Royal Bank of Canada cut TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price objective for the company. in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $2.62.



Shares of NYSEAMERICAN TRXC traded up $0.06 during trading on Friday, reaching $0.76. The stock had a trading volume of 192,778 shares, compared to its average volume of 2,582,441. TransEnterix, Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $6.98.

TransEnterix (NYSEAMERICAN:TRXC) last issued its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.01). The firm had revenue of $3.64 million during the quarter, compared to analyst estimates of $5.13 million.

TransEnterix Company Profile

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

See Also: Why are trading ranges significant?

Want to see what other hedge funds are holding TRXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransEnterix, Inc. (NYSEAMERICAN:TRXC).

Institutional Ownership by Quarter for TransEnterix (NYSEAMERICAN:TRXC)

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.